ORIC Pharmaceuticals Q1 net loss widens on higher R&D costs

ORIC Pharmaceuticals

04/05/2026 21:27

Overview

U.S. oncology drug developer's Q1 net loss widened as R&D expenses increased

Company ended Q1 with $419.7 mln in cash and investments, funding runway into 2H 2028

Selected Phase 3 dose for rinzimetostat and reported promising early clinical data

Outlook

ORIC expects to initiate Himalayas-1 Phase 3 trial for rinzimetostat in 1H 2026

Company anticipates rinzimetostat and enozertinib program updates in 2H 2026

ORIC expects cash and investments to fund operations into 2H 2028 and beyond

Result Drivers

R&D SPENDING - Higher R&D expenses driven by advancement of rinzimetostat and enozertinib clinical programs

CLINICAL PROGRESS - Selection of Phase 3 dose and promising early data for rinzimetostat supported continued investment

Company press release: ID:nGNX2QKcmv

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$35.77 mln
Q1 Income from Operations
-$39.62 mln
Q1 Operating Expenses
$39.62 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Oric Pharmaceuticals Inc is $22.00, about 125.2% above its May 1 closing price of $9.77

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)